IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-33788-7.html
   My bibliography  Save this article

Targeting EGFR-dependent tumors by disrupting an ARF6-mediated sorting system

Author

Listed:
  • Huiling Guo

    (School of Life Sciences, Xiamen University, Xiamen)

  • Juan Wang

    (Zhongshan Hospital, Fudan University)

  • Su Ren

    (School of Life Sciences, Xiamen University, Xiamen)

  • Lang-Fan Zheng

    (Zhongshan Hospital, Fudan University)

  • Yi-Xuan Zhuang

    (School of Life Sciences, Xiamen University, Xiamen)

  • Dong-Lin Li

    (School of Life Sciences, Xiamen University, Xiamen)

  • Hui-Hui Sun

    (School of Life Sciences, Xiamen University, Xiamen)

  • Li-Ying Liu

    (School of Life Sciences, Xiamen University, Xiamen)

  • Changchuan Xie

    (School of Life Sciences, Xiamen University, Xiamen)

  • Ya-Ying Wu

    (School of Life Sciences, Xiamen University, Xiamen)

  • Hong-Rui Wang

    (School of Life Sciences, Xiamen University, Xiamen)

  • Xianming Deng

    (School of Life Sciences, Xiamen University, Xiamen
    Xiamen University, Xiamen)

  • Peng Li

    (Zhongshan Hospital, Fudan University
    Zhengzhou University
    Shanghai Qi Zhi Institute)

  • Tong-Jin Zhao

    (Zhongshan Hospital, Fudan University
    Shanghai Qi Zhi Institute)

Abstract

Aberrant activation of EGFR due to overexpression or mutation is associated with poor prognosis in many types of tumors. Here we show that blocking the sorting system that directs EGFR to plasma membrane is a potent strategy to treat EGFR-dependent tumors. We find that EGFR palmitoylation by DHHC13 is critical for its plasma membrane localization and identify ARF6 as a key factor in this process. N-myristoylated ARF6 recognizes palmitoylated EGFR via lipid-lipid interaction, recruits the exocyst complex to promote EGFR budding from Golgi, and facilitates EGFR transporting to plasma membrane in a GTP-bound form. To evaluate the therapeutic potential of this sorting system, we design a cell-permeable peptide, N-myristoylated GKVL-TAT, and find it effectively disrupts plasma membrane localization of EGFR and significantly inhibits progression of EGFR-dependent tumors. Our findings shed lights on the underlying mechanism of how palmitoylation directs protein sorting and provide an potential strategy to manage EGFR-dependent tumors.

Suggested Citation

  • Huiling Guo & Juan Wang & Su Ren & Lang-Fan Zheng & Yi-Xuan Zhuang & Dong-Lin Li & Hui-Hui Sun & Li-Ying Liu & Changchuan Xie & Ya-Ying Wu & Hong-Rui Wang & Xianming Deng & Peng Li & Tong-Jin Zhao, 2022. "Targeting EGFR-dependent tumors by disrupting an ARF6-mediated sorting system," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33788-7
    DOI: 10.1038/s41467-022-33788-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-33788-7
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-022-33788-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Chiswili Chabu & Da-Ming Li & Tian Xu, 2017. "EGFR/ARF6 regulation of Hh signalling stimulates oncogenic Ras tumour overgrowth," Nature Communications, Nature, vol. 8(1), pages 1-10, April.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Yinshen Wee & Junhua Wang & Emily C. Wilson & Coulson P. Rich & Aaron Rogers & Zongzhong Tong & Evelyn DeGroot & Y. N. Vashisht Gopal & Michael A. Davies & H. Atakan Ekiz & Joshua K. H. Tay & Chris St, 2024. "Tumour-intrinsic endomembrane trafficking by ARF6 shapes an immunosuppressive microenvironment that drives melanomagenesis and response to checkpoint blockade therapy," Nature Communications, Nature, vol. 15(1), pages 1-18, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-33788-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.